Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: A case report

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of sodium phenylbutyrate (SPB) for hyperammonemia associated with congenital portosystemic shunt (CPSS) remains unknown. We show the effectiveness of oral SPB. Our patient had CPSS with severe hypoplasia of extrahepatic portal veins. At 9 months of age, to assess the efficacy of oral SPB, we evaluated the 24 h fluctuations of venous ammonia levels. In the first two days without SPB, ammonia levels were above 80 μmol/L for half a day. On the third and fourth days, administration of oral SPB three times a day decreased ammonia to acceptable levels, except at midnight. On the fifth day, another oral SPB administration at 8 pm decreased ammonia at midnight. Low levels of branched-chain amino acids, as well as coagulation disturbances, were observed without apparent symptoms. At 12 months of age, he showed normal psychomotor development. Oral SPB may be effective for hyperammonemia associated with CPSS.

Original languageEnglish
JournalJournal of Pediatric Endocrinology and Metabolism
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • Congenital portosystemic shunt
  • Hyperammonemia
  • Sodium phenylbutyrate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: A case report'. Together they form a unique fingerprint.

Cite this